Compare Boeing Co (BA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Illumina, Inc. — how do they compare? Boeing Co trades at $231.49 (market cap $184.35B), while Illumina, Inc. trades at $191.5 (market cap $29.12B). The key difference: Boeing Co is far larger — about 6.3× Illumina, Inc.'s market cap, and Boeing Co pays a 0.03% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BA | ILMN | |
|---|---|---|
Market Cap | $184.35B | $29.12B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $205.10 |
52-Week Low | $179.12 | $91.00 |
Enterprise Value | $210.23B | $30.48B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.14, down 0.28% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's fundamentals reflect a recovery, with 2025 revenue at $89.46B and net income of $2.24B, though valuation ratios like P/E of 83.9 remain elevated. News highlights Boeing's strategic sale of subsidiaries to Archer Aviation, aiming to streamline operations.
Outlook is cautiously optimistic with a consensus price target of $280.83, implying 21% upside. Key opportunities include production ramp-up and backlog growth, while risks involve high debt, volatile cash flows, and competitive pressures. Investors should monitor execution on profitability targets and macroeconomic impacts on aerospace demand.
Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
